Quantcast

Latest Cambridge Antibody Technology Stories

2008-10-28 09:00:40

BERKELEY, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Stephen K. Doberstein, Ph.D., to the position of Vice President of Research. In this position, Dr. Doberstein will be responsible for directing XOMA's preclinical drug candidates through the discovery and development process, where he will focus on antibody discovery and cell line development. He will also support...

2008-10-28 06:00:28

OSLO, Norway, October 28 /PRNewswire/ -- Affitech AS, the human therapeutic antibody company, today announced that it had acquired the full rights to the innovative diabody technology originally owned by Pharmexa A/S, a leading Danish immunotherapeutic and vaccine company. Also known as bi-specific single chain antibodies, diabodies are recombinant antibody-like proteins whose unique attributes make them attractive candidates for a variety of therapeutic applications. The acquisition follows...

2008-10-25 21:00:20

BERKELEY, Calif., Oct. 25, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that its poster titled "Efficacy Of XOMA 052 Anti-IL-1 Beta Antibody In The DBA/1 Mouse Collagen-Induced Arthritis Model" will be presented at the American College of Rheumatology 2008 Annual Conference, on Sunday, October 26 from 9:00 AM until 11:00 AM in Hall A. The poster also contains data demonstrating that XOMA 052 blocks...

2008-10-22 09:00:42

ImmunoCellular Therapeutics, a biotechnology company, has received two separate US patents relating to the company's monoclonal antibody therapeutics. The inventions cover methods for the detection of certain specific epitopes in the small cell lung cancer (SCLC) patient and for treating those patients with the company's monoclonal antibodies in a targeted manner. ImmunoCellular Therapeutics's (IMUC's) lead monoclonal antibody product candidate, ICT-109, which has demonstrated encouraging...

2008-10-21 09:00:54

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, announced the issuance of two separate U.S. patents relating to the company's monoclonal antibody therapeutics. Patents No. 7,435,415 and No. 7,435,554 are both entitled "Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer (SCLC)." The inventions cover methods for the detection of certain specific epitopes in the SCLC patient and for treating those patients...

2008-10-14 09:00:45

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, announced today that it has appointed Peter Brooks, Ph.D. and Sherie Morrison, Ph.D. to the company's Scientific Advisory Board. Dr. Brooks of the Maine Medical Center Research Institute brings extensive expertise in the monoclonal antibody area, having participated in the research and development of multiple anti-cancer compounds. Dr. Morrison of the University of California, Los Angeles is a world renowned...

2008-10-06 12:00:43

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue. Therapeutic Monoclonal Antibodies Report 2008-2023 http://www.reportlinker.com/p096392/Therapeutic-Monoclonal-Antibodies-Report-2008-2023.html This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and...

2008-09-26 09:00:40

4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschaeftsfuehrer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence. Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT's business development team he was responsible for numerous transactions with major...

2008-09-25 09:00:54

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, Inc., a privately held Los Angeles-based biotechnology company developing oncology products, today announced they have entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC platform technology, developed by Dr. Alan Epstein, M.D., Ph.D, for the development of therapeutic monoclonal antibodies. The technology enhances the human immune system's ability to produce an...

2008-09-23 09:01:09

KaloBios Pharmaceuticals, Inc. today announced that the company has raised $20 million in the first closing of its Series D venture financing. The financing was co-led by Mitsubishi UFJ Capital and Genzyme Ventures, both new investors, with the participation of the company's previous investors, MPM Capital, Alloy Ventures, GBS Ventures, Sofinnova Ventures, Singapore Bioinnovations, Pte., 5AM Ventures and Lotus Bioscience Ventures. "We are very pleased to complete this close in a very...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related